(S (NP (NP (DT The) (NN integration)) (PP (IN of) (NP (NP (NML (NN machine) (NN learning)) (NNS methods)) (PP (IN into) (NP (NN bioinformatics)))))) (VP (VBZ provides) (NP (JJ particular) (NNS benefits)) (PP (IN in) (S (VP (VBG identifying) (SBAR (WHADVP (WRB how)) (S (NP (NP (NNS therapeutics)) (PP (JJ effective) (IN in) (NP (CD one) (NN context)))) (VP (MD might) (VP (VB have) (NP (NN utility)) (PP (PP (IN in) (NP (DT an) (JJ unknown) (JJ clinical) (NN context))) (CC or) (PP (IN against) (NP (DT a) (JJ novel) (NN pathology)))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP aim) (S (VP (TO to) (VP (VB discover) (NP (NP (NP (DT the) (VBG underlying) (NNS associations)) (PP (IN between) (NP (JJ viral) (NNS proteins)))) (CC and) (NP (NP (JJ antiviral) (NNS therapeutics)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ effective) (PP (IN against) (NP (PRP them)))) (PP (IN by) (S (VP (VBG employing) (NP (JJ neural) (NN network) (NNS models)))))))))))))) (. .))
(S (S (VP (VBG Using) (NP (NP (DT the) (NML (NML (NNP National) (NNP Center)) (PP (IN for) (NP (NNP Biotechnology) (NNP Information)))) (NML (NN virus) (NN protein)) (NN database)) (CC and) (NP (NP (NP (DT the) (NNP DrugVirus) (NN database)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ provides) (NP (NP (DT a) (JJ comprehensive) (NN report)) (PP (IN of) (NP (NML (JJ broad) (HYPH -) (NN spectrum)) (JJ antiviral) (NNS agents)))))))) (-LRB- -LRB-) (NP (NNS BSAAs)) (-RRB- -RRB-)) (CC and) (NP (NP (NNS viruses)) (SBAR (S (NP (PRP they)) (VP (VBP inhibit)))))))) (, ,) (NP (PRP we)) (VP (VBD trained) (NP (NNP ANN) (NNS models)) (PP (IN with) (NP (NML (NN virus) (NN protein)) (NNS sequences))) (PP (IN as) (NP (NP (NNS inputs)) (CC and) (NP (NP (JJ antiviral) (NNS agents)) (VP (VBN deemed) (S (ADJP (ADJP (JJ safe) (HYPH -) (PP (IN in) (HYPH -) (NP (NNS humans)))) (PP (IN as) (NP (NNS outputs)))))))))) (. .))
(S (NP (NP (NN Model) (NN training)) (SBAR (S (VP (VP (VBD excluded) (NP (NP (NNP SARS)) (HYPH -) (NP (NNP CoV)) (HYPH -) (NP (CD 2) (NN proteins)))) (CC and) (VP (VBD included) (ADVP (RB only))))))) (VP (VBZ Phases) (NP (NML (NML (CD II)) (, ,) (NML (CD III)) (, ,) (NML (CD IV)) (CC and) (NML (VBN Approved) (NN level))) (NNS drugs))) (. .))
(S (S (VP (VBG Using) (NP (NNS sequences)) (PP (IN for) (NP (NP (NP (NNP SARS) (HYPH -) (NNP CoV) (HYPH -) (CD 2)) (-LRB- -LRB-) (NP (NP (DT the) (NN coronavirus)) (SBAR (WHNP (WDT that)) (S (VP (VBZ causes) (S (NP (NNP COVID) (HYPH -) (CD 19))))))) (-RRB- -RRB-)) (PP (IN as) (NP (NP (NNS inputs)) (PP (IN to) (NP (DT the) (VBN trained) (NNS models))))))))) (VP (VBZ produces) (NP (NP (NNS outputs)) (PP (IN of) (NP (JJ tentative) (ADJP (JJ safe) (HYPH -) (PP (IN in) (HYPH -) (ADJP (JJ human)))) (JJ antiviral) (NNS candidates)))) (PP (IN for) (S (VP (VBG treating) (NP (NN COVID) (HYPH -) (CD 19)))))) (. .))
(S (NP (PRP$ Our) (NNS results)) (VP (VBP suggest) (NP (JJ multiple) (NN drug) (NNS candidates)) (, ,) (SBAR (WHNP (NP (DT some)) (WHPP (IN of) (WHNP (WDT which)))) (S (NP (NP (NN complement) (JJ recent) (NNS findings)) (PP (IN from) (NP (JJ noteworthy) (JJ clinical) (NNS studies))))))) (. .))
(S (NP (NP (PRP$ Our) (NML (PP (IN in) (HYPH -) (NP (FW silico)))) (NN approach)) (PP (IN to) (NP (NN drug) (NN repurposing)))) (VP (VBZ has) (NP (NP (NN promise)) (PP (IN in) (S (VP (VBG identifying) (NP (JJ new) (NN drug) (NNS candidates) (CC and) (NNS treatments)) (PP (IN for) (NP (JJ other) (NNS viruses)))))))) (. .))
